Aichi Cancer Center, Nagoya, Japan.
Department of Gastroenterological Surgery II, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
J Hepatobiliary Pancreat Sci. 2021 Jan;28(1):26-54. doi: 10.1002/jhbp.870. Epub 2020 Dec 23.
The Japanese Society of Hepato-Biliary-Pancreatic Surgery launched the clinical practice guidelines for the management of biliary tract cancers (cholangiocarcinoma, gallbladder cancer, and ampullary cancer) in 2007, then published the 2nd version in 2014.
In this 3rd version, clinical questions (CQs) were proposed on six topics. The recommendation, grade for recommendation, and statement for each CQ were discussed and finalized by an evidence-based approach. Recommendations were graded as Grade 1 (strong) or Grade 2 (weak) according to the concepts of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system.
The 31 CQs covered the six topics: (a) prophylactic treatment, (b) diagnosis, (c) biliary drainage, (d) surgical treatment, (e) chemotherapy, and (f) radiation therapy. In the 31 CQs, 14 recommendations were rated strong and 14 recommendations weak. The remaining three CQs had no recommendation. Each CQ includes a statement of how the recommendations were graded.
This latest guideline provides recommendations for important clinical aspects based on evidence. Future collaboration with the cancer registry will be key for assessing the guidelines and establishing new evidence.
日本肝胆胰外科学会于 2007 年发布了胆道癌(胆管癌、胆囊癌和壶腹癌)管理临床实践指南,随后于 2014 年发布了第 2 版。
在第 3 版中,针对六个主题提出了临床问题(CQ)。通过循证方法对每个 CQ 的推荐、推荐等级和声明进行了讨论和最终确定。根据推荐评估、制定和评估(GRADE)系统的概念,推荐分为 1 级(强)或 2 级(弱)。
31 个 CQ 涵盖了六个主题:(a)预防性治疗,(b)诊断,(c)胆道引流,(d)手术治疗,(e)化疗和(f)放射治疗。在这 31 个 CQ 中,有 14 个推荐为强,14 个推荐为弱。其余三个 CQ 没有推荐。每个 CQ 都包含关于如何对推荐进行分级的说明。
本最新指南根据证据为重要的临床方面提供了建议。未来与癌症登记处的合作将是评估指南和建立新证据的关键。